Novelix Pharma.

Which are the latest news on Novelix Pharma.?

How big is Novelix Pharma.?

As of 10th June, Novelix Pharmaceuticals Ltd has a market capitalization of 181.00 Cr and reported Net Sales of 4.40 Cr with a Net Profit loss of 2.17 Cr over the latest four quarters. Shareholder's Funds were 7.40 Cr, and Total Assets were 8.67 Cr as of March 2022.

As of 10th June, Novelix Pharmaceuticals Ltd has a market capitalization of 181.00 Cr, categorizing it as a Micro Cap company.<BR><BR>In the latest four quarters, the company reported Net Sales of 4.40 Cr. However, it experienced a loss of 2.17 Cr in Net Profit during the same period.<BR><BR>The latest annual reporting period for the balance sheet is March 2022. Shareholder's Funds were recorded at 7.40 Cr, while Total Assets amounted to 8.67 Cr.

Who are in the management team of Novelix Pharma.?

The management team of Novelix Pharma includes Ravi Bhangadia (Chairman & Wholetime Director), Aditya Bhangadia (Managing Director), Arvind Kumar Bhangadia (Non-Executive Director), and independent directors Natwarlal Ramgopal Modani, Sagar Rajendra Karwa, and Monam Kapoor.

The management team of Novelix Pharma includes the following members:<BR><BR>1. **Ravi Bhangadia** - Chairman & Wholetime Director<BR>2. **ADITYA BHANGADIA** - Managing Director<BR>3. **Arvind Kumar Bhangadia** - Non Executive Director<BR>4. **Natwarlal Ramgopal Modani** - Independent Director<BR>5. **Sagar Rajendra Karwa** - Independent Director<BR>6. **Monam Kapoor** - Independent Director<BR><BR>If you have any more questions about the company or its operations, feel free to ask!

Why is Novelix Pharmaceuticals Ltd falling/rising?

As of 10-Jun, Novelix Pharmaceuticals Ltd's stock price has risen to 76.14, up 0.32%, driven by a 40.07% increase over the past week and strong investor interest, as evidenced by a 180.03% rise in delivery volume. The company's solid long-term growth and increased promoter stake further bolster confidence in its future prospects.

As of 10-Jun, Novelix Pharmaceuticals Ltd is experiencing a rise in its stock price, currently at 76.14, with a change of 0.24 (0.32%) upwards. This upward movement can be attributed to several positive factors. Over the past week, the stock has surged by 40.07%, significantly outperforming the Sensex, which has declined by 0.49%. In the last month, the stock has also shown a robust increase of 39.58%, while the benchmark has fallen by 4.33%. Year-to-date, Novelix Pharmaceuticals has delivered a return of 21.59%, contrasting with the Sensex's drop of 13.19%.<BR><BR>The stock has been on a consistent upward trend, gaining for six consecutive days and achieving a remarkable 45.43% return during this period. Additionally, it is trading above its 5-day, 20-day, 50-day, 100-day, and 200-day moving averages, indicating strong momentum. Investor participation has increased, with delivery volume rising by 180.03% compared to the 5-day average, suggesting heightened interest in the stock.<BR><BR>Furthermore, the company has demonstrated healthy long-term growth, with net sales increasing at an annual rate of 157.44%. Positive financial results over the last four quarters, including higher net sales and profit after tax, contribute to investor confidence. Promoter confidence is also on the rise, as they have increased their stake in the company by 1.14%, now holding 50.57%, which signals strong belief in the company's future prospects. Overall, these factors collectively explain the rising trend in Novelix Pharmaceuticals Ltd's stock price.

What does Novelix Pharma. do?

Novelix Pharmaceuticals Ltd is a micro-cap company in the retailing industry, reporting net sales of 25 Cr and a net profit of 1 Cr for March 2026. The company has a market cap of INR 181 Cr and a P/E ratio of 72.00.

Overview:<BR>Novelix Pharmaceuticals Ltd operates in the retailing industry as a micro-cap company.<BR><BR>History:<BR>The company was initially incorporated as 'Trimurthi Securities Limited' in 1994, underwent several name changes, and was last renamed to Novelix Pharmaceuticals Limited in 2025. The most recent quarterly results reported net sales and net profit for March 2026.<BR><BR>Financial Snapshot:<BR>- Net Sales: 25 Cr (Quarterly Results - Mar 2026)<BR>- Net Profit: 1 Cr (Quarterly Results - Mar 2026)<BR>- Market Cap: INR 181 Cr (Micro Cap)<BR><BR>Key Metrics:<BR>- P/E: 72.00<BR>- Industry P/E: 34<BR>- Dividend Yield: 0.00%<BR>- Debt Equity: -0.06<BR>- Return on Equity: 9.96%<BR>- Price to Book: 7.08<BR><BR>Contact Details:<BR>Address: 4-4-231/1/2/ABC Inderbagh, Sultan Bazar Hyderabad Telangana : 500095<BR>Tel: 91-40-24757370<BR>Email: info@trimurthidrugs.com<BR>Website: http://www.trimurthidrugs.com

Should I buy, sell or hold Novelix Pharmaceuticals Ltd?

When is the next results date for Novelix Pharmaceuticals Ltd?

The next results date for Novelix Pharmaceuticals Ltd is 29 May 2026.

The next results date for Novelix Pharmaceuticals Ltd is scheduled for 29 May 2026.

Are Novelix Pharmaceuticals Ltd latest results good or bad?

Novelix Pharmaceuticals Ltd's latest results show a return to profitability with a net profit of ₹1.00 crore and record net sales of ₹48.40 crores; however, concerns about low Return on Equity, high P/E ratio, and a low Mojo Score suggest caution regarding its long-term prospects.

Novelix Pharmaceuticals Ltd's latest results present a mixed picture. On one hand, the company has returned to profitability with a net profit of ₹1.00 crore in Q3 FY26, marking a significant turnaround from previous losses. Additionally, net sales reached ₹48.40 crores, the highest quarterly revenue in the company's history, which is a positive indicator of operational improvement.<BR><BR>However, despite these encouraging results, there are underlying concerns. The company's average Return on Equity (ROE) over the past five years is a mere 0.74%, indicating weak capital efficiency and a struggle to generate meaningful returns for shareholders. Furthermore, the stock's high P/E ratio of 114x suggests that it is currently overvalued relative to its earnings potential, raising questions about sustainability.<BR><BR>The company's Mojo Score is also low at 48 out of 100, leading to a "SELL" recommendation, reflecting ongoing concerns about its long-term fundamental strength. Additionally, the decline in promoter holding and the absence of institutional investors signal a lack of confidence in the company's future prospects.<BR><BR>In summary, while Novelix Pharmaceuticals has shown signs of recovery with its latest results, significant risks and valuation concerns remain, making the overall assessment cautious.

How has been the historical performance of Novelix Pharma.?

Novelix Pharma has experienced a declining trend in net sales and profitability, with significant losses reported since March 2020, including a net loss of -2.12 Cr in March 2022. Despite these challenges, the company's cash position improved, indicating some liquidity stability.

Answer:<BR>The historical performance of Novelix Pharma shows a declining trend in net sales and profitability over the past several years, with significant losses reported in recent periods.<BR><BR>Breakdown:<BR>Novelix Pharma's net sales have decreased from 10.50 Cr in March 2018 to 8.61 Cr in March 2022, reflecting a downward trend. The total operating income also followed this decline, dropping from 10.50 Cr in March 2018 to 8.61 Cr in March 2022. The company's total expenditure, excluding depreciation, peaked at 13.04 Cr in March 2021 but fell to 11.18 Cr in March 2022. Operating profit (PBDIT) has consistently been negative since March 2020, with a loss of -2.02 Cr reported in March 2022. Profit before tax and profit after tax also remained negative, with losses of -2.12 Cr and -2.12 Cr, respectively, in March 2022. The company's earnings per share (EPS) worsened from -0.01 in March 2017 to -2.22 in March 2022. Despite these challenges, the company's cash and cash equivalents improved from 0.59 Cr in March 2017 to 2.00 Cr in March 2022, indicating some liquidity stability. Overall, Novelix Pharma's financial performance has shown significant challenges, particularly in revenue generation and profitability, while maintaining a stable cash position.

Is Novelix Pharma. overvalued or undervalued?

As of November 27, 2025, Novelix Pharma is considered very expensive and overvalued with a PE ratio of 97.12, significantly higher than its peers, despite a strong stock performance of 148.52% over the past year.

As of 27 November 2025, the valuation grade for Novelix Pharma has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company is currently assessed as overvalued, with a PE ratio of 97.12, an EV to EBIT of 70.40, and an EV to EBITDA of 68.28. These ratios are starkly higher than its peers, such as Sun Pharma with a PE of 37.62 and Divi's Lab at 69.34, both categorized as very expensive.<BR><BR>In comparison to its industry peers, Novelix Pharma's valuation metrics suggest it is not only overvalued but also out of sync with more attractively priced competitors like Cipla and Dr Reddy's Labs, which have PE ratios of 22.67 and 18.08, respectively. While Novelix has shown impressive stock performance over the past year with a return of 148.52% compared to the Sensex's 6.84%, this does not justify its current high valuation levels.

Who are the top shareholders of the Novelix Pharma.?

The top shareholders of Novelix Pharma are Srinidhi Fine-chemicals LLP with 38.67%, followed by Mallela Venkatramna Reddy at 11.6%, and individual investors holding 36.84%. There are currently no mutual funds or foreign institutional investors involved.

The top shareholders of Novelix Pharma include Srinidhi Fine-chemicals LLP, which holds the largest stake at 38.67%. The highest public shareholder is Mallela Venkatramna Reddy, who owns 11.6%. Additionally, individual investors collectively hold 36.84% of the company's shares. There are no mutual funds or foreign institutional investors currently holding shares in the company.

Who are the peers of the Novelix Pharma.?

Novelix Pharma's peers include Khemani Distrib., M K Exim India, MRP Agro, and others, with varying management risks and growth rates. Notably, Novelix Pharma has the highest 1-year return at 138.43%, significantly outperforming its peers.

Peers: The peers of Novelix Pharma are Khemani Distrib., M K Exim India, MRP Agro, Sattva Sukun, Silgo Retail, Purv Flexi, Magson Retail, Osia Hyper Reta., Fonebox Retail, and Cell Point.<BR><BR>Quality Snapshot: Excellent management risk is observed at Khemani Distrib., M K Exim India, MRP Agro, Magson Retail, and Osia Hyper Reta., while Average management risk is found at Cell Point. Below Average management risk is noted for Novelix Pharma., Sattva Sukun, Silgo Retail, Purv Flexi, and Fonebox Retail. Growth is Excellent at M K Exim India and Osia Hyper Reta., Good at MRP Agro and Sattva Sukun, while Below Average growth is seen at Novelix Pharma., Silgo Retail, Purv Flexi, and the rest. Capital Structure is Excellent at Khemani Distrib. and M K Exim India, Good at MRP Agro and Sattva Sukun, while Below Average capital structure is noted for Novelix Pharma., Silgo Retail, Purv Flexi, and the rest.<BR><BR>Return Snapshot: The peer with the highest 1-year return is Novelix Pharma. at 138.43%, while the lowest is M K Exim India at -4.79%. Novelix Pharma.'s 1-year return significantly outperforms all peers. Additionally, Sattva Sukun, MRP Agro, and Silgo Retail have negative six-month returns.

What is the technical trend for Novelix Pharma.?

As of May 27, 2025, Novelix Pharma's technical trend is mildly bullish, supported by positive momentum from the MACD and RSI, although caution is advised due to a mildly bearish KST.

As of 27 May 2025, the technical trend for Novelix Pharma has changed from bullish to mildly bullish. The weekly MACD and RSI are both bullish, indicating positive momentum in the short term. The daily moving averages also reflect a bullish stance. However, the KST on a weekly basis is mildly bearish, suggesting some caution. The Bollinger Bands show a mildly bullish trend weekly and bullish monthly, while the Dow Theory indicates no trend weekly but mildly bullish monthly. Overall, the current stance is mildly bullish, supported by strong monthly indicators and daily moving averages, despite some mixed signals from the KST.